Cancer Immunotherapy Pill Could Be On the Horizon

AHA Publisher — Wed, 17 Aug 2022 07:00:04 +0000

Brian Blum via Israel21c – Immunotherapy — activating the immune system to fight cancer — has been one of the most significant developments in the world of cancer treatment. But it still isn’t a cure-all, and scientists have been working to improve its delivery and efficacy. A recent breakthrough by Israeli and Portuguese scientists could result in cancer immunotherapy in a pill form that wouldn’t require a hospital stay or intravenous injection, would be less expensive, and may offer other benefits as well. Researchers at Tel Aviv University and the University of Lisbon, led in Israel by Prof. Ronit Satchi-Fainaro, head of the center for cancer biology research and the laboratory for cancer research and nanomedicine at TAU’s medical school, developed a synthetic molecule that is many magnitudes smaller than even the most advanced immunotherapy antibodies. The small size allows the molecule to penetrate and reach less accessible and less exposed areas of solid tumors. Moreover, unlike traditional immunotherapy antibodies, which have a hard time surviving the harsh acidity of the intestinal tract, the new molecules “have been designed especially to be resilient and not degrade in the gut, which opens up the exciting possibility of giving them orally,” explains Satchi-Fainaro. Most immunotherapy medications must travel through blood vessels to reach the tumor. The new tiny molecules can find their way to the target by diffusion without needing the “road” of blood vessels. The small synthetic molecules also would be much less expensive to produce at large scale than are today’s biological-based immunotherapy drugs, potentially enabling many more people to access immunotherapy. “We have already synthesized the small molecule with simple equipment, in a short time and at a fraction of the cost,” Satchi-Fainaro notes. Allowing patients to take the drug orally at home will also bring down the price by eliminating hospital costs. As described in the Journal for ImmunoTherapy of Cancer, the team has tested the molecule in vitro as well as on a human tumor in a special lab model, but not yet with actual patients. A commercial product is still years away, as further development and human testing is needed. ISRAEL21c has written about Satchi-Fainaro’s research on numerous occasions. She was featured in our article on bio-convergence. More recently, she has identified ways to treat melanoma and glioblastoma, an aggressive brain cancer. The current research was supported by Fundação para a Ciência e a Tecnologia, Ministério da Ciência, Tecnologia e Ensino Superior (FCT-MCTES), the Israeli Ministry of Health, La Caixa Foundation, Liga Portuguesa Contra o Cancro, the ERC, the Israel Science Foundation, the Melanoma Research Alliance, the Israel Cancer Research Fund Professorship Award and the Morris Kahn Foundation. To read the original article click here.

The post Cancer Immunotherapy Pill Could Be On the Horizon appeared first on Amazing Health Advances.

Has Israel Just Found the Cure for Covid?

AHA Publisher — Tue, 09 Feb 2021 08:00:39 +0000

Abigail Klein Leichman via Israel21c – Even with Israel’s world-leading rollout of Covid-19 vaccinations, drugs to treat Covid patients are in desperate need across the world. Two such drugs developed in Israel show great promise in clinical trials: EXO-CD24 and Allocetra. EXO-CD24, an experimental inhaled medication developed at Tel Aviv Sourasky Medical Center, cured all 30 moderate-to-severe cases in a Phase I clinical trial. Developed over the past six months at the hospital, EXOCD24 stops the “cytokine storm” – where the immune system goes out of control and starts attacking healthy cells – that occurs in the lungs of 5-7% of Covid-19 patients. “To date, the preparation has been tried with great success on 30 severe patients, in 29 of whom the medical condition improved within two to three days and most of them were discharged home within three to five days. The 30th patient also recovered but after a longer time,” the hospital reports. “The drug is based on exosomes, [vesicles] that are released from the cell membrane and used for intercellular communication. We enrich the exosomes with 24CD protein. This protein is expressed on the surface of the cell and has a known and important role in regulating the immune system,” explained Dr. Shiran Shapira, director of the laboratory of Prof. Nadir Arber, who has been researching the CD24 protein for over two decades. “The preparation is given by inhalation, once a day, for only a few minutes, for five days,” Shapira said. She said the experimental treatment has two unique characteristics. The first is that it inhibits the over-secretion of cytokines. The second is that it is delivered directly to the lungs and therefore has no systemic side effects that injected or oral drugs can cause. “Even if the vaccines perform their function, and even if no new mutations are produced then still in one way or another the corona will remain with us,” said Arber, director of the medical center’s Integrated Cancer Prevention Center. “To this end, we have developed a unique drug, EXO-CD24.” Arber added that this advanced preparation “can be produced quickly and efficiently and at a very low cost in every pharmaceutical facility in the country, and in a short time globally.” Prof. Ronni Gamzu, CEO of the medical center, said, “Prof. Arber’s results for first-phase research were excellent and gave us all confidence in the method he has been researching [here] for many years. I personally assisted him in further obtaining the approvals from the Ministry of Health for further research.” Allocetra Meanwhile, Enlivex Therapeutics last week reported positive results from a multi-center Phase II clinical trial of its experimental Covid-19 immunotherapy drug Allocetra in severe and critical Covid-19 patients. We reported in October that five Covid-19 intensive care patients were discharged from Hadassah University Medical Center in Jerusalem after treatment with Allocetra. Nine severe and seven critical Covid-19 patients were treated with Allocetra in the Phase II clinical trial. Fourteen of them recovered and were discharged from the hospital after an average of 5.3 days. The Phase II trial originally was expected to enroll 24 patients but was “completed early in support of anticipated accelerated regulatory filings of the trial’s positive safety and efficacy data,” Enlivex reported. Altogether, 19 out of 21 Phase II and Phase Ib Allocetra trial patients recovered and were discharged from the hospital after an average of 5.6 days. Most of the patients in both studies had pre-existing risk factors such as male gender, obesity and hypertension. “The results we have seen from the 12 Covid-19 patients treated to date with Allocetra are exciting,” said Prof. Vernon van Heerden, head of the General Intensive Care Unit at Hadassah and the lead investigator of both clinical trials. “The Phase II patients who have been discharged from the hospital are currently healthy. We believe that these compelling results have demonstrated the safety and efficacy of Allocetra in these complicated patients, highlighting the potential of Enlivex’s product candidate to benefit severe and critical Covid-19 patients as well as others suffering from cytokine storms and organ dysfunctions across various clinical indications.” Allocetra is based on the research of Enlivex chief scientific and medical officer Dr. Dror Mevorach, head of internal medicine and of one of Hadassah’s coronavirus wards. It works by restoring balance to the immune system. Mevorach said Allocetra “may have utility as a safe and efficacious treatment … regardless of the specific coronavirus mutation that afflicted the patients, and across different life-threatening, high mortality clinical indications with high unmet medical needs.” To read the original article click here. For more articles from Israel21c click here.

The post Has Israel Just Found the Cure for Covid? appeared first on Amazing Health Advances.

immunotherapy drug Archives - Amazing Health Advances

Cancer Immunotherapy Pill Could Be On the Horizon

Has Israel Just Found the Cure for Covid?